Identification

Name
Medroxyprogesterone acetate
Accession Number
DB00603  (APRD00627)
Type
Small Molecule
Groups
Approved, Investigational
Description

Medroxyprogesterone acetate (INN, USAN, BAN), also known as 17α-hydroxy-6α-methylprogesterone acetate, and commonly abbreviated as MPA, is a steroidal progestin, a synthetic variant of the human hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis as well as several other indications. MPA is a more potent derivative of its parent compound medroxyprogesterone (MP). While medroxyprogesterone is sometimes used as a synonym for medroxyprogesterone acetate, what is normally being administered is MPA and not MP. [Wikipedia]

Structure
Thumb
Synonyms
  • (6alpha)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dione
  • 17-Acetoxy-6alpha-methylprogesterone
  • 17-Acetoxy-6α-methylprogesterone
  • 17alpha-Hydroxy-6alpha-methylprogesterone acetate
  • 17α-hydroxy-6α-methylprogesterone acetate
  • 6-alpha-Methyl-17-alpha-acetoxyprogesterone
  • 6-alpha-Methyl-17-alpha-hydroxyprogesterone acetate
  • 6alpha-Methyl-17-acetoxy progesterone
  • 6alpha-Methyl-17alpha-hydroxyprogesterone acetate
  • 6alpha-Methyl-4-pregnene-3,20-dion-17alpha-ol acetate
  • 6α-Methyl-17-acetoxy progesterone
  • 6α-Methyl-17α-hydroxyprogesterone acetate
  • Medroxyacetate progesterone
  • Medroxyprogesterone 17-acetate
  • Medroxyprogesterone acetate
  • Methylacetoxyprogesterone
  • Metigestrona
  • MPA
External IDs
NSC-21171 / NSC-26386
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Depo-ProveraInjection, suspension400 mg/mLIntramuscularPharmacia & Upjohn Inc1960-11-01Not applicableUs
Depo-ProveraInjection, suspension150 mg/mLIntramuscularA S Medication Solutions1992-10-29Not applicableUs
Depo-ProveraInjection, suspension150 mg/mLIntramuscularA S Medication Solutions1992-10-292017-06-20Us
Depo-ProveraInjection, suspension150 mg/mLIntramuscularPharmacia & Upjohn Inc1992-10-29Not applicableUs
Depo-ProveraInjection, suspension400 mg/mLIntramuscularPhysicians Total Care, Inc.1995-01-13Not applicableUs
Depo-ProveraInjection, suspension150 mg/mLIntramuscularPharmacia & Upjohn Inc1992-10-29Not applicableUs
Depo-ProveraInjection, suspension150 mg/mLIntramuscularA S Medication Solutions1992-10-292017-06-20Us
Depo-ProveraInjection, suspension150 mg/mLIntramuscularA S Medication Solutions1992-10-29Not applicableUs
Depo-provera Sterile Aqueous Suspension 150 mg/mlSuspension150 mgIntramuscularPfizer1995-12-31Not applicableCanada
Depo-provera Sterile Aqueous Suspension 50 mg/mlSuspension50 mgIntramuscularPfizer1960-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-medroxyTablet10 mgOralApotex Corporation2007-01-10Not applicableCanada
Apo-medroxyTablet100 mgOralApotex Corporation2005-08-04Not applicableCanada
Apo-medroxy TabletsTablet2.5 mgOralApotex Corporation2002-04-22Not applicableCanada
Apo-medroxy TabletsTablet5 mgOralApotex Corporation2002-04-22Not applicableCanada
Medroxyprogesterone AcetateTablet10 mg/1OralAmerincan Health Packaging2015-03-31Not applicableUs
Medroxyprogesterone AcetateTablet10 mg/1OralAidarex Pharmaceuticals LLC1996-12-04Not applicableUs
Medroxyprogesterone AcetateTablet5 mg/1OralBarr Laboratories1996-12-03Not applicableUs
Medroxyprogesterone AcetateTablet2.5 mg/1Oralbryant ranch prepack1996-12-04Not applicableUs
Medroxyprogesterone AcetateTablet10 mg/1OralRed Pharm Drug, Inc.1996-12-04Not applicableUs
Medroxyprogesterone AcetateTablet10 mg/1OralRebel Distributors1996-08-09Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Medroxyprogesterone AcetateTablet10 mg/1OralNu Care Pharmaceuticals,inc.1996-12-04Not applicableUs
International/Other Brands
Depo-subq provera 104
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
PremphaseMedroxyprogesterone acetate + Conjugated estrogensKitWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2012-03-01Not applicableUs
PremplusMedroxyprogesterone acetate (5.0 mg) + Conjugated estrogens (0.625 mg)Kit; TabletOralPfizer2002-05-09Not applicableCanada
PremplusMedroxyprogesterone acetate (2.5 mg) + Conjugated estrogens (0.625 mg)Kit; TabletOralPfizer2000-10-30Not applicableCanada
Premplus CycleMedroxyprogesterone acetate (10 mg) + Conjugated estrogens (0.625 mg)Kit; TabletOralPfizerNot applicableNot applicableCanada
PremproMedroxyprogesterone acetate (2.5 mg/1) + Conjugated estrogens (.625 mg/1)Tablet, sugar coatedOralPhysicians Total Care, Inc.1996-06-20Not applicableUs
PremproMedroxyprogesterone acetate (2.5 mg/1) + Conjugated estrogens (.625 mg/1)Tablet, sugar coatedOralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2009-09-21Not applicableUs
PremproMedroxyprogesterone acetate (1.5 mg/1) + Conjugated estrogens (.45 mg/1)Tablet, sugar coatedOralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.2009-09-21Not applicableUs
PremproMedroxyprogesterone acetate (1.5 mg/1) + Conjugated estrogens (.3 mg/1)Tablet, sugar coatedOralDispensing Solutions, Inc.2009-09-21Not applicableUs
PremproMedroxyprogesterone acetate (2.5 mg/1) + Conjugated estrogens (.625 mg/1)Tablet, sugar coatedOralAvera Mc Kennan Hospital2016-01-28Not applicableUs
PremproMedroxyprogesterone acetate (1.5 mg/1) + Conjugated estrogens (.45 mg/1)Tablet, sugar coatedOralPhysicians Total Care, Inc.2003-07-25Not applicableUs
Categories
UNII
C2QI4IOI2G
CAS number
71-58-9
Weight
Average: 386.5244
Monoisotopic: 386.245709576
Chemical Formula
C24H34O4
InChI Key
PSGAAPLEWMOORI-PEINSRQWSA-N
InChI
InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1
IUPAC Name
(1S,2R,8S,10R,11S,14R,15S)-14-acetyl-2,8,15-trimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl acetate
SMILES

Pharmacology

Indication

Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens.

Structured Indications
Pharmacodynamics

Medroxyprogesterone acetate is a synthetic progestin more potent than progesterone.

Mechanism of action

Progestins diffuse freely into target cells in the female reproductive tract, mammary gland, hypothalamus, and the pituitary and bind to the progesterone receptor. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge.

TargetActionsOrganism
AProgesterone receptor
agonist
Human
AEstrogen receptor alpha
agonist
Human
Absorption

Rapidly absorbed from GI tract

Volume of distribution
Not Available
Protein binding

90%

Metabolism

Hepatic

Route of elimination

Following oral dosing, MPA is extensively metabolized in the liver via hydroxylation, with subsequent conjugation and elimination in the urine. Most MPA metabolites are excreted in the urine as glucuronide conjugates with only minor amounts excreted as sulfates.

Half life

50 days

Clearance
  • 64110 +/- 42662 mL/min [postmenopausal women under fasting conditions with a single Dose of 2 × 10 mg]
  • 74123 +/- 35126 mL/min [postmenopausal women under fasting conditions with a single Dose of 8 × 2.5 mg]
  • 41963 +/- 38402 mL/min [postmenopausal women following daily administration of one PROVERA 10 mg tablet for 7 days]
Toxicity

Side effects include loss of bone mineral density, BMD changes in adult women, bleeding irregularities, cancer risks, and thromboembolic disorders.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Medroxyprogesterone acetate.Investigational
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Medroxyprogesterone acetate.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
AcenocoumarolMedroxyprogesterone acetate may decrease the anticoagulant activities of Acenocoumarol.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Medroxyprogesterone acetate.Investigational, Withdrawn
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Experimental
AcitretinThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Acitretin.Approved
AdapaleneThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Medroxyprogesterone acetate.Experimental, Investigational
AlitretinoinThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Alitretinoin.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Medroxyprogesterone acetate.Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Medroxyprogesterone acetate.Approved
AmiodaroneThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Amiodarone.Approved, Investigational
AmobarbitalThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Medroxyprogesterone acetate.Approved, Investigational
AncrodThe therapeutic efficacy of Ancrod can be decreased when used in combination with Medroxyprogesterone acetate.Investigational
Antithrombin III humanThe therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Medroxyprogesterone acetate.Approved
ApixabanThe therapeutic efficacy of Apixaban can be decreased when used in combination with Medroxyprogesterone acetate.Approved
AprepitantThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Aprepitant.Approved, Investigational
ArdeparinThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational, Withdrawn
ArgatrobanThe therapeutic efficacy of Argatroban can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Medroxyprogesterone acetate.Approved, Investigational
ArtemetherThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Artemether.Approved
AtazanavirThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Atomoxetine.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Medroxyprogesterone acetate.Investigational
BarbexacloneThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Barbexaclone.Experimental
BarbitalThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Barbital.Illicit
BecaplerminThe therapeutic efficacy of Becaplermin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Medroxyprogesterone acetate.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Medroxyprogesterone acetate.Approved, Investigational
BexaroteneThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Bexarotene.Approved, Investigational
BivalirudinThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
BoceprevirThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Bosentan.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Medroxyprogesterone acetate.Investigational, Withdrawn
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Medroxyprogesterone acetate.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.Approved
CarbamazepineThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Carbamazepine.Approved, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Medroxyprogesterone acetate.Experimental
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Medroxyprogesterone acetate.Experimental
CeritinibThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Ceritinib.Approved
CertoparinThe therapeutic efficacy of Certoparin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Medroxyprogesterone acetate.Approved
CholestyramineThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Cholestyramine.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Medroxyprogesterone acetate.Experimental
Citric AcidThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Clobazam.Approved, Illicit
ClorindioneMedroxyprogesterone acetate may decrease the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Cobicistat.Approved
ColesevelamThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Colestipol.Approved
Conestat alfaMedroxyprogesterone acetate may increase the thrombogenic activities of Conestat alfa.Approved
ConivaptanThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Medroxyprogesterone acetate.Approved, Investigational
CyclosporineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Experimental
Dabigatran etexilateThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Medroxyprogesterone acetate.Approved
DabrafenibThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Dabrafenib.Approved
DalteparinThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Medroxyprogesterone acetate.Approved
DanaparoidThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Withdrawn
DarexabanThe therapeutic efficacy of Darexaban can be decreased when used in combination with Medroxyprogesterone acetate.Investigational
DarunavirThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Medroxyprogesterone acetate.Investigational
DesirudinThe therapeutic efficacy of Desirudin can be decreased when used in combination with Medroxyprogesterone acetate.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Approved
DextranThe therapeutic efficacy of Dextran can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Vet Approved
Dextran 40The therapeutic efficacy of Dextran 40 can be decreased when used in combination with Medroxyprogesterone acetate.Approved
Dextran 70The therapeutic efficacy of Dextran 70 can be decreased when used in combination with Medroxyprogesterone acetate.Approved
Dextran 75The therapeutic efficacy of Dextran 75 can be decreased when used in combination with Medroxyprogesterone acetate.Approved
DicoumarolMedroxyprogesterone acetate may decrease the anticoagulant activities of Dicoumarol.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Approved
DihydroergotamineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Diltiazem.Approved
DiphenadioneMedroxyprogesterone acetate may decrease the anticoagulant activities of Diphenadione.Experimental
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Medroxyprogesterone acetate.Approved, Investigational
DoxycyclineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Dronedarone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Medroxyprogesterone acetate.Approved
Edetic AcidThe therapeutic efficacy of Edetic Acid can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Vet Approved
EdoxabanThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Medroxyprogesterone acetate.Approved
EfavirenzThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Efavirenz.Approved, Investigational
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.Approved
EnoxaparinThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Medroxyprogesterone acetate.Approved
EnzalutamideThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Eslicarbazepine acetate.Approved
Ethyl biscoumacetateMedroxyprogesterone acetate may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
FelbamateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Felbamate.Approved
Ferulic acidThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Medroxyprogesterone acetate.Experimental
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Medroxyprogesterone acetate.Approved
FluconazoleThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Fluconazole.Approved
FluindioneMedroxyprogesterone acetate may decrease the anticoagulant activities of Fluindione.Investigational
FluvoxamineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxThe therapeutic efficacy of Fondaparinux can be decreased when used in combination with Medroxyprogesterone acetate.Investigational
Fondaparinux sodiumThe therapeutic efficacy of Fondaparinux sodium can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
FosamprenavirThe serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Medroxyprogesterone acetate resulting in a loss in efficacy.Approved
FosaprepitantThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Fosaprepitant.Approved
FosphenytoinThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Fusidic Acid.Approved
GabexateThe therapeutic efficacy of Gabexate can be decreased when used in combination with Medroxyprogesterone acetate.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Medroxyprogesterone acetate.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Medroxyprogesterone acetate.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Medroxyprogesterone acetate.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Medroxyprogesterone acetate.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Medroxyprogesterone acetate.Approved
GriseofulvinThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Griseofulvin.Approved, Vet Approved
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Medroxyprogesterone acetate.Investigational
HeparinThe therapeutic efficacy of Heparin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
HexobarbitalThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Hexobarbital.Approved
Human C1-esterase inhibitorMedroxyprogesterone acetate may increase the thrombogenic activities of Human C1-esterase inhibitor.Approved
IdelalisibThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe therapeutic efficacy of Idraparinux can be decreased when used in combination with Medroxyprogesterone acetate.Investigational
ImatinibThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Imatinib.Approved
IndinavirThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Indinavir.Approved
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Medroxyprogesterone acetate.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Medroxyprogesterone acetate.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Medroxyprogesterone acetate.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Medroxyprogesterone acetate.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Medroxyprogesterone acetate.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Medroxyprogesterone acetate.Approved
IsavuconazoniumThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsotretinoinThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Isotretinoin.Approved
IsradipineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Ketoconazole.Approved, Investigational
LamotrigineThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Lamotrigine.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Experimental
LepirudinThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Medroxyprogesterone acetate.Approved
LetaxabanThe therapeutic efficacy of Letaxaban can be decreased when used in combination with Medroxyprogesterone acetate.Investigational
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Medroxyprogesterone acetate.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Medroxyprogesterone acetate.Approved
LopinavirThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Lopinavir.Approved
LovastatinThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Lumacaftor.Approved
MelagatranThe therapeutic efficacy of Melagatran can be decreased when used in combination with Medroxyprogesterone acetate.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Medroxyprogesterone acetate.Approved
MethohexitalThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Methohexital.Approved
MethylphenobarbitalThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Methylphenobarbital.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Experimental
MetreleptinThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Metreleptin.Approved
MifepristoneThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Medroxyprogesterone acetate.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Medroxyprogesterone acetate.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
MitotaneThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Mitotane.Approved
Mycophenolic acidThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Mycophenolic acid.Approved
NadroparinThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Medroxyprogesterone acetate.Approved
NafamostatThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
NefazodoneThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Nevirapine.Approved
NilotinibThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Nilotinib.Approved, Investigational
OlaparibThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Experimental, Investigational
OsimertinibThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Osimertinib.Approved
OtamixabanThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Medroxyprogesterone acetate.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Approved
OxcarbazepineThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Oxcarbazepine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Medroxyprogesterone acetate.Approved, Vet Approved
PalbociclibThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Palbociclib.Approved
Pentaerythritol TetranitrateThe therapeutic efficacy of Pentaerythritol Tetranitrate can be decreased when used in combination with Medroxyprogesterone acetate.Approved
PentobarbitalThe metabolism of Medroxyprogesterone acetate can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Medroxyprogesterone acetate.Approved
PerampanelThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Perampanel.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Experimental
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational, Withdrawn
PhenindioneMedroxyprogesterone acetate may decrease the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Medroxyprogesterone acetate can be increased when combined with Phenobarbital.Approved
PhenprocoumonMedroxyprogesterone acetate may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Phenytoin.Approved, Vet Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
PosaconazoleThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
PrimidoneThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Primidone.Approved, Vet Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.Experimental
Protein CThe therapeutic efficacy of Protein C can be decreased when used in combination with Medroxyprogesterone acetate.Approved
Protein S humanThe therapeutic efficacy of Protein S human can be decreased when used in combination with Medroxyprogesterone acetate.Approved
ProtocatechualdehydeThe therapeutic efficacy of Protocatechualdehyde can be decreased when used in combination with Medroxyprogesterone acetate.Approved
PrucaloprideThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Prucalopride.Approved
RanolazineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Ranolazine.Approved, Investigational
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
ReviparinThe therapeutic efficacy of Reviparin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
RifabutinThe metabolism of Medroxyprogesterone acetate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Medroxyprogesterone acetate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Medroxyprogesterone acetate can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Rifaximin.Approved, Investigational
RivaroxabanThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Medroxyprogesterone acetate.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
SaquinavirThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Medroxyprogesterone acetate.Approved
SecobarbitalThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Medroxyprogesterone acetate.Approved, Investigational, Vet Approved
SildenafilThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Simeprevir.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.Investigational
St. John's WortThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Stiripentol.Approved
SugammadexThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Sugammadex.Approved
SulfisoxazoleThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
TelaprevirThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Telithromycin.Approved
ThalidomideMedroxyprogesterone acetate may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Thiamylal.Approved, Vet Approved
ThiopentalThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Thiopental.Approved, Vet Approved
TiclopidineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Ticlopidine.Approved
TioclomarolMedroxyprogesterone acetate may decrease the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Medroxyprogesterone acetate.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Medroxyprogesterone acetate.Approved
TopiramateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Topiramate.Approved
Tranexamic AcidMedroxyprogesterone acetate may increase the thrombogenic activities of Tranexamic Acid.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Medroxyprogesterone acetate.Approved, Investigational
TretinoinThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Tretinoin.Approved, Investigational, Nutraceutical
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Medroxyprogesterone acetate.Investigational, Withdrawn
TroxerutinThe therapeutic efficacy of Troxerutin can be decreased when used in combination with Medroxyprogesterone acetate.Investigational
UlipristalThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Ulipristal.Approved
VenlafaxineThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
VoriconazoleThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinMedroxyprogesterone acetate may decrease the anticoagulant activities of Warfarin.Approved
XimelagatranThe therapeutic efficacy of Ximelagatran can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Take with food.

References

Synthesis Reference

Klaus ANNEN, Thomas Linz, Karl-Heinz Neff, Rolf Bohlmann, Henry Laurent, "PROCESS FOR PREPARING 17ALPHA-ACETOXY-6-METHYLENEPREGN-4-ENE-3,20-DIONE, MEDROXYPROGESTERONE ACETATE AND MEGESTROL ACETATE." U.S. Patent US20090012321, issued January 08, 2009.

US20090012321
General References
  1. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH: Classification and pharmacology of progestins. Maturitas. 2008 Sep-Oct;61(1-2):171-80. [PubMed:19434889]
  2. Lenco W, Mcknight M, Macdonald AS: Effects of cortisone acetate, methylprednisolone and medroxyprogesterone on wound contracture and epithelization in rabbits. Ann Surg. 1975 Jan;181(1):67-73. [PubMed:1119869]
External Links
KEGG Drug
D00951
KEGG Compound
C08150
PubChem Compound
6279
PubChem Substance
46508895
ChemSpider
6043
BindingDB
50067678
ChEBI
6716
ChEMBL
CHEMBL717
Therapeutic Targets Database
DAP001211
PharmGKB
PA450344
IUPHAR
2879
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Medroxyprogesterone
ATC Codes
G03AC06 — MedroxyprogesteroneG03FA12 — Medroxyprogesterone and estrogenG03AA08 — Medroxyprogesterone and ethinylestradiolG03DA02 — MedroxyprogesteroneG03FB06 — Medroxyprogesterone and estrogenL02AB02 — Medroxyprogesterone
AHFS Codes
  • 68:32.00 — Progestins
FDA label
Download (1.2 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingPreventionContraception2
1CompletedNot AvailableHealthy Volunteers1
1CompletedHealth Services ResearchOne to five years postmenopausal1
1CompletedPreventionHIV Prevention1
1CompletedTreatmentEstrogen Replacement Therapy1
1CompletedTreatmentOne to five years postmenopausal1
1RecruitingBasic ScienceDiabetes, Diabetes Mellitus Type 11
1TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1, 2CompletedTreatmentEndometriosis1
1, 2RecruitingBasic ScienceTransplantation, Kidney1
1, 2RecruitingTreatmentAdult Living Donor Kidney Transplant Recipients / Living Kidney Donors / Transplant, Kidney1
2Active Not RecruitingTreatmentAdvanced, Persistent, or Recurrent Endometrial Cancer1
2CompletedPreventionEndometrial Cancers1
2CompletedPreventionEndometrial Safety / Vasomotor Symptoms1
2CompletedTreatmentClinically Diagnosed Endometriotic Patient Was Defined as a Woman Who Has Pelvic Pain and at Least One Evidence of PV or TVS1
2CompletedTreatmentEndometrial Adenocarcinomas / Endometrial Adenosquamous Carcinoma / Endometrial Cancers / Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation / Recurrent Uterine Corpus Carcinoma / Stage I Uterine Corpus Cancer / Stage II Uterine Corpus Cancer / Stage III Uterine Corpus Cancer / Stage IV Uterine Corpus Cancer1
2CompletedTreatmentEndometriosis1
2CompletedTreatmentEpilepsies / Menopause1
2CompletedTreatmentEstrogen Receptor-negative Breast Cancer / Progesterone Receptor-negative Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentHypertensive / One to five years postmenopausal / Pre-Hypertension1
2CompletedTreatmentInfection, Human Immunodeficiency Virus I1
2CompletedTreatmentMenopausal Hot Flushes / Menopause1
2RecruitingTreatmentGrade 1 Endometrial Endometrioid Adenocarcinoma / Grade 2 Endometrial Endometrioid Adenocarcinoma / Grade 3 Endometrial Endometrioid Adenocarcinoma / Uterine Corpus Adenosarcoma1
2SuspendedTreatmentCrohn's Disease (CD)1
2TerminatedPreventionEndometrial Cancers1
2, 3CompletedHealth Services ResearchCardiovascular Disease (CVD) / Coronary Arteriosclerosis / Coronary Heart Disease (CHD) / Heart Diseases1
2, 3CompletedTreatmentAlzheimer's Disease (AD)1
2, 3CompletedTreatmentHealthy Volunteers1
2, 3CompletedTreatmentSleep Apnea Syndrome1
2, 3RecruitingTreatmentDelayed Graft Function1
2, 3RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
3CompletedOtherPostmenopausal Women1
3CompletedPreventionBone destruction / Bone Diseases / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / Hypercholesterolaemia / Hypertensive / Myocardial Ischemia / One to five years postmenopausal / Thrombosis1
3CompletedPreventionCancer, Breast / Endometrial Cancers1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Arteriosclerosis / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia / One to five years postmenopausal1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia / One to five years postmenopausal1
3CompletedSupportive CareCancer, Breast / Menopausal Hot Flushes / Menopausal Symptoms1
3CompletedSupportive CareMenopausal Hot Flushes1
3CompletedTreatmentAdenocarcinoma, Prostate1
3CompletedTreatmentHypermenorrhea1
3CompletedTreatmentBone destruction / Menopause1
3CompletedTreatmentMetastatic Renal Cell Carcinoma1
3CompletedTreatmentRejection, Transplant / Transplantation, Kidney1
3CompletedTreatmentRenal Cancers1
3CompletedTreatmentTurner's Syndrome1
3CompletedTreatmentBone destruction1
3Not Yet RecruitingTreatmentHeavy Menstrual Bleeding / Improve Quality of Life1
3RecruitingPreventionInfertilities1
3RecruitingTreatmentDysfunctional Uterine Bleeding1
3RecruitingTreatmentHypermenorrhea1
3RecruitingTreatmentPrimary Ovarian Insufficiency1
3TerminatedTreatmentSystemic Lupus Erythematosus (SLE)1
4Active Not RecruitingHealth Services ResearchContraception1
4Active Not RecruitingTreatmentChronic Kidney Disease (CKD) / End Stage Renal Disease (ESRD) / Hemodialysis-dependent patients / Renal Replacement Therapies / Transplantation, Renal1
4CompletedPreventionAdverse Effects / Transplantation, Kidney1
4CompletedPreventionCardiovascular Disease (CVD)1
4CompletedTreatmentApoptotic Signal Pathways in Endometrial Hyperplasia1
4CompletedTreatmentDysfunctional Uterine Bleeding1
4CompletedTreatmentEndometriosis1
4CompletedTreatmentHeart Transplantation1
4CompletedTreatmentInfertilities1
4CompletedTreatmentRenal Transplanted Recipients1
4CompletedTreatmentTransplant, Kidney1
4Not Yet RecruitingTreatmentGastrointestinal Disorder, Functional / Kidney Transplant Rejection1
4RecruitingOtherRenal Failure1
4RecruitingTreatmentEBV / Transplant; Failure, Kidney1
4RecruitingTreatmentOvulatory Dysfunction1
4TerminatedTreatmentDysfunctional Uterine Bleeding1
4TerminatedTreatmentTransplantation, Renal1
4Unknown StatusTreatmentEndometrial Hyperplasia1
Not AvailableActive Not RecruitingNot AvailableContraception / Human Immunodeficiency Virus (HIV) / Immune Cells (Mucosal and Systemic) / Microbiota1
Not AvailableCompletedNot AvailableContraception1
Not AvailableCompletedNot AvailableDementia Syndromes1
Not AvailableCompletedPreventionContraception1
Not AvailableCompletedSupportive CareContraception / Postpartum Period1
Not AvailableCompletedTreatmentDeficiency, Vitamin D / Polycystic Ovarian Syndrome1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
Not AvailableCompletedTreatmentHypermenorrhea / Uterine Hemorrhage1
Not AvailableCompletedTreatmentSystemic Lupus Erythematosus (SLE)1
Not AvailableRecruitingNot AvailableContraception / Contraceptive implant therapy / IUD / Post coital contraception1
Not AvailableRecruitingNot AvailableFemale Sexual Function1
Not AvailableRecruitingBasic ScienceCardiovascular Disease (CVD) / Cognitive Impairments / Endothelial Dysfunction / Executive Dysfunction1
Not AvailableRecruitingTreatmentInfertilities / Polycystic Ovaries Syndrome1
Not AvailableTerminatedNot AvailableInitiation of Depo-Provera (DMPA) / Initiation of Mirena (LNG-IUD) / Initiation of Oral Contraception (OC)1
Not AvailableTerminatedBasic ScienceFibromyalgia1
Not AvailableTerminatedTreatmentPolycystic Ovarian Syndrome1
Not AvailableTerminatedTreatmentTransplantation, Kidney1

Pharmacoeconomics

Manufacturers
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Barr laboratories inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Usl pharma inc
  • Pharmacia and upjohn co
Packagers
Dosage forms
FormRouteStrength
TabletOral100 mg
Injection, suspensionIntramuscular150 mg/mL
Injection, suspensionIntramuscular400 mg/mL
SuspensionIntramuscular150 mg
SuspensionIntramuscular50 mg
Injection, suspensionSubcutaneous104 mg/.65mL
TabletOral10 mg/1
TabletOral2.5 mg/1
TabletOral5 mg/1
Kit
Kit; tabletOral
Tablet, sugar coatedOral
TabletOral2.5 mg
TabletOral5 mg
TabletOral10 mg
Prices
Unit descriptionCostUnit
Depo-Provera 400 mg/ml Suspension 2.5ml Vial201.13USD vial
Depo-subq provera 104 syringe108.17USD syringe
Depo-provera 400 mg/ml vial96.7USD ml
Depo-Provera 150 mg/ml Suspension 1ml Syringe94.58USD syringe
MedroxyPROGESTERone Acetate 150 mg/ml Suspension 1ml Syringe60.56USD syringe
MedroxyPROGESTERone Acetate 150 mg/ml Suspension 1ml Vial55.17USD vial
Depo-Provera 150 mg/ml31.02USD ml
Medroxyprogesterone Acetate 150 mg/ml23.05USD ml
Medroxyprogesterone ace powder18.97USD g
Depo-Provera 50 mg/ml6.01USD ml
Provera 10 mg tablet2.03USD tablet
Provera 5 mg tablet1.57USD tablet
Provera 100 mg Tablet1.41USD tablet
Provera 2.5 mg tablet1.15USD tablet
Apo-Medroxy 100 mg Tablet0.96USD tablet
Provera 10 mg Tablet0.73USD tablet
MedroxyPROGESTERone Acetate 10 mg tablet0.51USD tablet
MedroxyPROGESTERone Acetate 5 mg tablet0.48USD tablet
MedroxyPROGESTERone Acetate 2.5 mg tablet0.43USD tablet
Medroxyprogesterone 10 mg tablet0.4USD tablet
Provera 5 mg Tablet0.36USD tablet
Medroxyprogesterone 5 mg tablet0.33USD tablet
Apo-Medroxy 10 mg Tablet0.33USD tablet
Novo-Medrone 10 mg Tablet0.33USD tablet
Medroxyprogesterone 2.5 mg tablet0.32USD tablet
Provera 2.5 mg Tablet0.18USD tablet
Apo-Medroxy 5 mg Tablet0.16USD tablet
Novo-Medrone 5 mg Tablet0.16USD tablet
Apo-Medroxy 2.5 mg Tablet0.08USD tablet
Novo-Medrone 2.5 mg Tablet0.08USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2409059No2006-04-182021-04-25Canada
US6495534No2000-05-152020-05-15Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)214.5 °CPhysProp
water solubility22.2mg/LNot Available
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00221 mg/mLALOGPS
logP3.42ALOGPS
logP4.13ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)17.82ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area60.44 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity107.81 m3·mol-1ChemAxon
Polarizability44.05 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9959
Blood Brain Barrier+0.9617
Caco-2 permeable+0.651
P-glycoprotein substrateSubstrate0.6107
P-glycoprotein inhibitor IInhibitor0.9149
P-glycoprotein inhibitor IIInhibitor0.7016
Renal organic cation transporterNon-inhibitor0.7753
CYP450 2C9 substrateNon-substrate0.8642
CYP450 2D6 substrateNon-substrate0.908
CYP450 3A4 substrateSubstrate0.7744
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.8907
CYP450 2D6 inhibitorNon-inhibitor0.9532
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8095
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.899
Ames testNon AMES toxic0.9775
CarcinogenicityNon-carcinogens0.9273
BiodegradationNot ready biodegradable0.9354
Rat acute toxicity1.8121 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9429
hERG inhibition (predictor II)Non-inhibitor0.7761
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-002r-0449000000-c09cb0607e4a6118f05d
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dj-3940000000-2c9513d9a6a2092f5759
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00di-3930000000-453ace561b4dc5712e85
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-009i-2947000000-2c9190ea372fd54323e9
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Steroid esters / 20-oxosteroids / 3-oxo delta-4-steroids / Delta-4-steroids / Cyclohexenones / Alpha-acyloxy ketones / Carboxylic acid esters / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Progestogin-skeleton / Steroid ester / 20-oxosteroid / 3-oxo-delta-4-steroid / 3-oxosteroid / Oxosteroid / Delta-4-steroid / Cyclohexenone / Alpha-acyloxy ketone / Carboxylic acid ester
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
steroid ester (CHEBI:6716)

Targets

Details
1. Progesterone receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
Gene Name
PGR
Uniprot ID
P06401
Uniprot Name
Progesterone receptor
Molecular Weight
98979.96 Da
References
  1. Risch HA, Bale AE, Beck PA, Zheng W: PGR +331 A/G and increased risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1738-41. [PubMed:16985038]
  2. Madauss KP, Stewart EL, Williams SP: The evolution of progesterone receptor ligands. Med Res Rev. 2007 May;27(3):374-400. [PubMed:17013809]
  3. Gizard F, Robillard R, Gross B, Barbier O, Revillion F, Peyrat JP, Torpier G, Hum DW, Staels B: TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. Mol Cell Biol. 2006 Oct;26(20):7632-44. [PubMed:17015480]
  4. Wu HB, Fabian S, Jenab S, Quinones-Jenab V: Progesterone receptors activation after acute cocaine administration. Brain Res. 2006 Dec 18;1126(1):188-92. Epub 2006 Nov 15. [PubMed:17109827]
  5. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP: The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol. 2007 Feb;21(2):359-75. Epub 2006 Nov 30. [PubMed:17138644]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
Gene Name
ESR1
Uniprot ID
P03372
Uniprot Name
Estrogen receptor
Molecular Weight
66215.45 Da
References
  1. Jain JK, Li A, Yang W, Minoo P, Felix JC: Mifepristone alters expression of endometrial steroid receptors and their cofactors in new users of medroxyprogesterone acetate. Fertil Steril. 2007 Jan;87(1):8-23. Epub 2006 Nov 7. [PubMed:17094978]
  2. Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, Hwang ES: Type and duration of exogenous hormone use affects breast cancer histology. Ann Surg Oncol. 2007 Feb;14(2):695-703. Epub 2006 Nov 14. [PubMed:17103262]
  3. Lessey BA, Palomino WA, Apparao KB, Young SL, Lininger RA: Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women. Reprod Biol Endocrinol. 2006;4 Suppl 1:S9. [PubMed:17118173]
  4. Yuri T, Tsukamoto R, Uehara N, Matsuoka Y, Tsubura A: Effects of different durations of estrogen and progesterone treatment on development of N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats. In Vivo. 2006 Nov-Dec;20(6B):829-36. [PubMed:17203775]
  5. Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T, Dermime S: Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer. 2007 Aug 15;121(4):751-8. [PubMed:17415709]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhang JW, Liu Y, Zhao JY, Wang LM, Ge GB, Gao Y, Li W, Liu HT, Liu HX, Zhang YY, Sun J, Yang L: Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate. Drug Metab Dispos. 2008 Nov;36(11):2292-8. doi: 10.1124/dmd.108.022525. Epub 2008 Aug 25. [PubMed:18725509]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid delta-isomerase activity
Specific Function
3-beta-HSD is a bifunctional enzyme, that catalyzes the oxidative conversion of Delta(5)-ene-3-beta-hydroxy steroid, and the oxidative conversion of ketosteroids. The 3-beta-HSD enzymatic system pl...
Gene Name
HSD3B2
Uniprot ID
P26439
Uniprot Name
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2
Molecular Weight
42051.845 Da
References
  1. Lee TC, Miller WL, Auchus RJ: Medroxyprogesterone acetate and dexamethasone are competitive inhibitors of different human steroidogenic enzymes. J Clin Endocrinol Metab. 1999 Jun;84(6):2104-10. [PubMed:10372718]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34